Radboud University Nijmegen Medical Centre
Nijmegen, 6500 HB, Netherlands
NCT Number: NCT01551511
Abdominal pain resulting from chronic pancreatitis (CP) is often recurrent, intense and long-lasting, and is extremely difficult to treat. Medical analgesic therapy is considered as first choice in pain management of CP, resulting in regularly prescription of opioids. The adverse consequences of prolonged opioid use, including addiction, tolerance and opioid induced hyperalgesia, call for an alternative medical treatment. Cannabis has been used to treat pain for many centuries. Delta-9-tetrahydrocannabinol (Δ9-THC), the psychoactive substance of the cannabis plant, has been shown in previous studies to be a promising analgesic. The development of Namisol®, a tablet containing purified Δ9-THC showing an improved pharmacokinetic profile, provides the opportunity to test the analgesic potential of Δ9-THC in favourable conditions. The current study aims to investigate the analgesic efficacy of Namisol® as add-on analgesic during a long-term treatment (52 days) of abdominal pain resulting from CP.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Nijmegen, 6500 HB, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
Other names: Namisol, Dronabinol
Identical step-up approach to the Namisol arm.
Time frame: Baseline versus day 52
The primary outcome measure is defined as the reduction in average VAS pain scores at the end of the study (day 50-52) compared to the pre-treatment level between the Namisol® and placebo group, measured by a Visual Analoge Scale (VAS) in a daily pain diary.
Time frame: Baseline and day 52
Electroencephalogram; measuring evoked potentials to noxious electrical stimuli, evoked potentials to auditory stimuli (oddball), and FFT of spontaneous EEG.
Time frame: Baseline versus day 15 and day 52
Quantitative Sensory Testing; measuring pressure pain thresholds, electrical thresholds, electric wind-up response, and DNIC.
Time frame: Baseline until follow-up (day 59-61)
Time frame: Predose levels at baseline, day 15 and day 52; postdose levels (30 min, 45 min, 60 min, 100 min) at day 15 and 52
THC, 11-OH-THC and THC-COOH concentrations
Time frame: Baseline until day 52
Time frame: Baseline versus day 52
Quality of life will be evaluated by questionnaires
Time frame: Baseline versus day 15 and day 52
Pharmacodynamics measured by body sway and questionnaires (VASBond & Lader and VASBowdle)
Radboud University Medical Center
Other
Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03070210
Abdominal Pain, Chronic Disease
Cleveland, Ohio, United States
View Trial DetailsNCT05289362
Chronic Disease, Digestive System Diseases
Shanghai, China
View Trial DetailsNCT05270434
Chronic Disease, Digestive System Diseases
Shanghai, China
View Trial DetailsNCT06907953
COVID-19, Chronic Disease
New York, United States
View Trial Details